Fertility and Sterility
Volume 91, Issue 5 , Pages 1654-1656, May 2009

Return to fertility after cessation of a continuous oral contraceptive

  • Kurt Barnhart, M.D., M.S.C.E.

      Affiliations

    • Department of Obstetrics and Gynecology, PENN Fertility Care, University of Pennsylvania, Philadelphia, Pennsylvania
    • Corresponding Author InformationReprint requests: Kurt Barnhart, M.D., M.S.C.E., 3701 Market St., Ste. 801, Philadelphia, PA 19104 (FAX: 215-615-4200).
  • ,
  • Sebastian Mirkin, M.D.

      Affiliations

    • Women's Health, Clinical Research and Development, Wyeth Research, Collegeville, Pennsylvania
  • ,
  • Gary Grubb, M.D., M.P.H.

      Affiliations

    • Women's Health, Clinical Research and Development, Wyeth Research, Collegeville, Pennsylvania
  • ,
  • Ginger Constantine, M.D.

      Affiliations

    • Women's Health, Clinical Research and Development, Wyeth Research, Collegeville, Pennsylvania

Received 15 October 2007; received in revised form 8 February 2008; accepted 13 February 2008. published online 07 May 2008.

Objective

To evaluate the return to fertility among women planning to become pregnant after the use of a continuous regimen of levonorgestrel 90 μg and ethinyl E2 20 μg.

Design

Descriptive analysis of pregnancy outcomes after participation in a contraceptive trial.

Setting

Multicenter trial.

Subject(s)

Participants in a phase 3 contraceptive trial who discontinued to become pregnant.

Intervention(s)

Eligible subjects were contacted at 3 and 12 months after treatment discontinuation to determine if and when they had conceived.

Main Outcome Measure(s)

Kaplan-Meier analysis displaying the time until conception after oral contraceptive discontinuation.

Result(s)

In the phase 3 trial, 34 of 2,134 subjects cited a desire for pregnancy as a reason for discontinuation. Of these, 4 were already pregnant before stopping treatment, 4 initiated other contraception, and 5 were lost to follow-up. Of the remaining 21 subjects at risk of pregnancy, the pregnancy rate was 57% at 3 months, 81% at 12 months, and 86% (18 of 21) (95% confidence interval 64% to 97%) at 13 months after discontinuation of treatment.

Conclusion(s)

These findings suggest that a continuous oral contraceptive with levonorgestrel 90 μg and ethinyl E2 20 μg does not delay the return to fertility.

Key Words: Return to fertility, oral contraceptive, low-dose, continuous, noncyclic

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by a grant from Wyeth Research, Collegeville, Pa.

 K.B. was an investigator for this poststudy follow-up and received research funding from Wyeth Research, Collegeville, Pa. Other sources of research funding and/or financial relationships include Novo Nordisk (consultant), Organon (speaker and investigator), Johnson & Johnson, Duramed, Xanodyne, Boehringer Ingelheim, Third Wave, Pfizer, and MGI Pharma (investigator). S.M., G.G., and G.C. are employees of Wyeth Research. Other financial affiliation for G.G. is Johnson & Johnson. S.M. and G.C. have no other financial affiliation to disclose.

PII: S0015-0282(08)00484-6

doi:10.1016/j.fertnstert.2008.02.122

Fertility and Sterility
Volume 91, Issue 5 , Pages 1654-1656, May 2009